Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma

Journal of Lipid Research

Volumn 49, Issue 1, 2008, Pages 245-250

  Connelly, Philip W ^a,b   Maguire, Graham F ^a   Picardo, Clive M ^a,b   Teiber, John F ^c   Draganov, Dragomir ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WIL RESEARCH LABORATORIES   (United States)

Author keywords

High density lipoproteins; Lipoproteins; Quantitation; Western blot

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; DITHIOTHREITOL; EDETIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4C10; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; CHOLESTEROL, LDL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LIPOPROTEINS, VLDL; TRIGLYCERIDES;

EID: 38049170542     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D700022-JLR200     Document Type: Article

References (26)

1. James, R. W. 2006. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin. Chem. Lab. Med. 44: 1052-1059.
2. Carlson, C. S., P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. 2006. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J. Lipid Res. 47: 1014-1024.
3. Costa, L. G., A. Vitalone, T. B. Cole, and C. E. Furlong. 2005. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 69: 541-550.
4. Leviev, I., O. Poirier, V. Nicaud, A. Evans, F. Kee, D. Arveiler, C. Morrison, F. Cambien, and R. W. James. 2002. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis. 161: 463-467.
5. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68: 1428-1436.
6. Blatter Garin, M. C., C. Abbott, S. Messmer, M. Mackness, P. Durrington, D. Pometta, and R. W. James. 1994. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 304: 549-554.
7. Ng, C. J., D. M. Shih, S. Y. Hama, N. Villa, M. Navab, and S. T. Reddy. 2005. The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med. 38: 153-163.
8. Aviram, M., and M. Rosenblat. 2005. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr. Opin. Lipidol. 16: 393-399.
9. James, R. W., I. Leviev, and A. Righetti. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 101: 2252-2257.
10. van der Gaag, M. S., A. van Tol, L. M. Scheek, R. W. James, R. Urgert, G. Schaafsma, and H. F. Hendriks. 1999. Daily moderate alcohol consumption increases serum paraoxonase activity: a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis. 147: 405-410.
11. Kuo, C. L., and B. N. La Du. 1995. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23: 935-944.
12. Kujiraoka, T., T. Oka, M. Ishihara, T. Egashira, T. Fujioka, E. Saito, N. E. Miller, and H. Hattori. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J. Lipid Res. 41: 1358-1363.
13. Mackness, B., G. K. Davies, W. Turkie, E. Lee, D. H. Roberts, E. Hill, C. Roberts, P. N. Durrington, and M. I. Mackness. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21: 1451-1457.
14. Abbott, C. A., M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
15. Mackness, B., M. I. Mackness, S. Arrol, W. Turkie, K. Julier, B. Abuasha, J. E. Miller, A. J. Boulton, and P. N. Durrington. 1998. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 139: 341-349.
16. Garin, M. C., R. W. James, P. Dussoix, H. Blanche, P. Passa, P. Froguel, and J. Ruiz. 1997. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
17. James, R. W., I. Leviev, J. Ruiz, P. Passa, P. Froguel, and M. C. Garin. 2000. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes. 49: 1390-1393.
18. Mackness, B., P. N. Durrington, B. Abuashia, A. J. Boulton, and M. I. Mackness. 2000. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. (Lond.). 98: 355-363.
19. Kordonouri, O., R. W. James, B. Bennetts, A. Chan, Y. L. Kao, T. Danne, M. Silink, and K. Donaghue. 2001. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism. 50: 657-660.
20. Boemi, M., I. Leviev, C. Sirolla, C. Pieri, M. Marra, and R. W. James. 2001. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis. 155: 229-235.
21. Mackness, B., P. N. Durrington, A. J. Boulton, D. Hine, and M. I. Mackness. 2002. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur. J. Clin. Invest. 32: 259-264.
22. Inoue, M., T. Suehiro, T. Nakamura, Y. Ikeda, Y. Kumon, and K. Hashimoto. 2000. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism. 49: 1400-1405.
23. Ayub, A., M. I. Mackness, S. Arrol, B. Mackness, J. Patel, and P. N. Durrington. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19: 330-335.
24. Mackness, B., P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
25. Suehiro, T., Y. Ikeda, T. Shiinoki, M. Inoue, Y. Kumon, T. Itahara, and K. Hashimoto. 2002. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J. Atheroscler. Thromb. 9: 133-138.
26. Ikeda, Y., T. Suehiro, T. Itahara, Y. Inui, H. Chikazawa, M. Inoue, K. Arii, and K. Hashimoto. 2007. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin. Nephrol. 67: 358-365.